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Abstract
Introduction: In randomly assigned studies with EGFR TKI only a minor proportion of patients with NSCLC have genetically
profiled biopsies. Guidelines provide evidence to perform EGFR and KRAS mutation analysis in non-squamous NSCLC. We
explored tumor biopsy quality offered for mutation testing, different mutations distribution, and outcome with EGFR TKI.
Patient and Methods: Clinical data from 8 regional hospitals were studied for patient and tumor characteristics, treatment
and overall survival. Biopsies sent to the central laboratory were evaluated for DNA quality and subsequently analyzed for
mutations in exons 18–21 of EGFR and exon 2 of KRAS by bidirectional sequence analysis.
Results: Tumors from 442 subsequent patients were analyzed. For 74 patients (17%) tumors were unsuitable for mutation
analysis. Thirty-eight patients (10.9%) had EGFR mutations with 79% known activating mutations. One hundred eight
patients (30%) had functional KRAS mutations. The mutation spectrum was comparable to the Cosmic database. Following
treatment in the first or second line with EGFR TKI median overall survival for patients with EGFR (n = 14), KRAS (n = 14)
mutations and wild type EGFR/KRAS (n = 31) was not reached, 20 and 9 months, respectively.
Conclusion: One out of every 6 tumor samples was inadequate for mutation analysis. Patients with EGFR activating
mutations treated with EGFR-TKI have the longest survival.
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Introduction
The effect of EGFR tyrosine kinase inhibitors (TKI) in patients
with non-small-cell lung cancer (NSCLC) depends on the EGFR
mutation status. Therefore, selecting the adequate tumor specimen
for mutational analysis is an important issue in making treatment
decisions in NSCLC. In previous randomized studies comparing
EGFR TKI therapy to regular chemotherapy, the proportion of
patients with adequate tumor tissue for analysis ranged from 10 to
38% [1,2,3,4,5,6]. Most randomized studies used different EGFR
mutation tests that only examined a very limited number of
hotspot mutations such as L858R and exon 19 deletions
[2,7,8,9,10]. What happened with less frequent mutations is not
always obvious. As EGFR mutations are only present in non-
squamous NSCLC [11], accurate histological phenotyping is
mandatory in order to make decisions on the type of chemother-
apy and for predicting the a priori presence of mutations. The
IASLC/ATS/ERS guideline recommends mutational testing in
non-squamous NSCLC [12].
In Caucasian patients with non-squamous cell lung carcinoma,
the KRAS mutation is most common (20–30% of cases) [13,14],
followed in frequency by mutations in the EGFR gene (10–20% of
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cases) [13,15]. Within histological phenotypes, certain features
appear to be associated with specific mutations, for example the
micropapillary aspect of adenocarcinoma with BRAF V600
mutations [16]. Although it is advantageous for patients with
activating EGFR mutations to receive EGFR TKI
[2,3,8,17,18,19], in patients with other types of genetic aberrations
this treatment is not effective. For example, in a study on patients
with EML4-ALK translocations a lack of tumor response to EGFR
TKI was reported [20]. However, for NSCLC patients with
KRAS mutations the evidence is inconclusive. Several studies
showed a complete lack of response to treatment with an EGFR
TKI [17,21,22], one study demonstrated that NSCLC patients
with tumors harboring KRAS mutations had a similar outcome to
either EGFR TKI or chemotherapy [3]. Tumors with KRAS
mutations have been shown to have worse outcome compared to
patients with wild type KRAS (WT) both when treated with
surgery [23] or with chemotherapy [24].
The aim is to study the distribution of common and rare EGFR
and KRAS mutations sent from 8 regional hospitals to the
university pathology department. The quality of tumor biopsies
sent in for mutational analysis was assessed and mutation status
was related to treatment with EGFR TKI outcome.
Methods
Patients
This study concerns all the NSCLC tumor samples from eight
regional Dutch hospitals during the period of November 2008
until April 2011 that were tested for mutational status by a central
pathology department. Data on gender, smoking status, age at
diagnosis, stage at diagnosis, localization of metastases, start date
and (different) lines of treatment received were collected. Tumor
samples were obtained by either bronchoscopy, transthoracic lung
biopsies and/or from pulmonary resections and were sent to the
respective pathology department for histological examination.
Histology was according to 2004 WHO criteria [25]. Response to
treatment was performed according to RECIST criteria [26].
Sample collection procedure and DNA extraction
From each formalin-fixed and paraffin embedded (FFPE) tumor
tissue block that was sent to the pathology department 4 mm
sections were cut. After hematoxylin and eosin staining, slides were
evaluated by an experienced lung pathologist for the presence of
sufficient tumor tissue and estimating the percentage of tumor
cells. Samples with clearly less than 50% tumor cells were defined
as inadequate for EGFR/KRAS mutation testing. Areas with
.50% tumor cells marked by the pathologist on the slide. This
area was scraped from the slide using a scalpel and dissolved in
TE-4 and 20 mg/ml Proteinase K (Life Technologies, Grand
Island, NY, USA). DNA was extracted by incubation overnight at
55uC, followed by heating to 100uC for 5 minutes to inactivate
proteinase K and centrifuged at room temperature at 13,000 rpm.
The aqueous solution was directly used for PCR analysis or stored
at 220uC. DNA concentration was measured on a ND1000
spectrophotometer (Nanodrop, Wilmington, DE, USA). All DNA
isolates were set to 10 ng/ml in TE-4 prior to use. For quality
control, genomic DNA was amplified in a multiplex PCR
containing a control gene primer set resulting in products of
100, 200, 300, 400 and 600 bp according to the BIOMED-2
protocol [27]. Only DNA samples with PCR products of 300 bp
and larger were used for mutation analysis. All samples were tested
on DNA extracted from two independent slides (duplicates). All
standard precautions were taken to avoid contamination of
amplification products using separate laboratories for pre- and
post-PCR handling. To avoid cross-contamination, a new
microtome blade was used each time a new sample was sectioned.
Either direct sequencing or high resolution melting (HRM) with
confirmatory direct sequencing was performed according to
protocol. Identical mutations in forward and reverse sequencing
was required before a positive result is reported. The protocol is
detailed in Appendix S1. The primers used for direct sequencing
or HRM are described in supplemental table 1.
Informed Consent and Ethics
When patients first visited the outpatient department, written
informed consent for blood and tumor tissue was obtained for
mutational analysis. EGFR and KRAS tests were performed as
part of routine diagnostic approach and the outcome of these tests
was documented in the patient file and communicated with
patients. Because this is a retrospective study to collect and analyze
clinical patient data, under the Dutch Law for human medical
research (WMO), no consent was necessary from the medical
ethics committee. Data were coded and not traceable to the
individual patient.
Statistics
Descriptive statistics were performed for patient and tumor
characteristics. Frequencies of common and rare mutations were
tabulated. The frequency of EGFR and KRAS mutations were
compared with available data on lung tissue from the Catalogue
Of Somatic Mutations In Cancer database, (Cosmic DB; http://
www.sanger.ac.uk/genetics/CGP/cosmic/). The relation between
the presence or absence of mutations and the occurrence of most
common tumor metastases was determined using the two sided
Fisher exact test. For this particular analysis the patients with
either an EGFR or a KRAS mutation were compared with
patients who were scored as being both EGFR and KRAS WT.
Overall survival (OS) was calculated from the date of diagnosing
stage IV disease until censorship or death. Only patients with
available clinical data who had progressed to stage IV disease and
subsequently were treated were included for survival analysis. All
patients treated with an EGFR TKI irrespective of their
mutational status were evaluated for overall survival.
Univariate Cox regression analysis was performed with the
covariates age, gender, histology (presence of adenocarcinoma,
squamous cell and large cell carcinoma), KRAS and EGFR
Table 1. Patient and tumor characteristics from samples sent
to central laboratory for mutation analysis.
N Percentage
Number of patients 442 100




Large cell undifferentiated 42 9
Adenosquamous 7 1
Carcinoid 3 1
Salivary gland 2 1
NSCLC-NOS 8 2
SCC is squamous cell lung carcinoma. NSCLC-NOS is non-small cell lung cancer
– not otherwise specified.
doi:10.1371/journal.pone.0070346.t001
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mutation status, metastatic site (brain, bone, lung) were also
analyzed. Variables with p-value less than 0.20 were used for the
multivariate analysis.
All statistical analysis was performed using SPSS version 18.0.
Nominal P-values less than 0.05 were considered significant.
Results
EGFR and KRAS mutations
From November 2008 until April 2011 474 samples from 442
patients were sent to the central pathology department for
mutation analysis. The most common histological classification
was adenocarcinoma (80%), 8% of the samples came from
histological subtypes not associated with EGFR mutations
(Table 1).
Two hundred and twenty one patients (60.1% of all tested
patients, 50% of all patients) were EGFR and KRAS WT. Thirty
eight patients (10.9% of all tested patients, 8.6% of all patients) had
an EGFR mutation (Table 2). In 5 patients, 2 different EGFR
mutations coincided in the same tumor tissue resulting in a total of
43 mutations. Thirty of 38 patients with EGFR mutations (79%)
were activating EGFR mutations. Only one patient had a T790M
mutation in the primary tumor. TTF-1 positive adenocarcinomas
showed an EGFR mutation more often than those who were TTF-
1 negative (26/150 vs 1/50, Fisher’s exact 2-sided test, p=0.01).
A total of 110 of patients (30% of all tested patients, 24% of all
patients) had a KRAS mutation with G12C (41%) and G12V
(18%) being the most frequent mutations and showing a similar
distribution as in the Cosmic database (Table 3). We also found 1
(1%) rare KRAS mutation in codon 13, (p.G13Y). In addition, 2
patients had KRAS mutations outside the hotspot (p.V14L and
p.L19F), these are non-functional. This means that in a total of
108 patients a functional KRAS mutation was detected in our
cohort. The comparison of mutational results in the different
subtypes of NSCLC in our population is shown in table 4.
Quality of tumor samples for mutation analysis
Seventy five tumor samples ((16%) were not adequate for
mutation analysis. In 59 samples tissue contained less than 50%
tumor cells (mostly because of extensive intermingling inflamma-
tion) and in 16 the quality of DNA appeared unsuitable for
mutation testing. In 4 of these patients an adequate tissue sample
was yielded by re-biopsy. In 3 tumors no further mutation analysis
Table 2. Distribution of EGFR mutations in advanced non-squamous cell lung carcinoma.
Type of EGFR mutation Sensitivity Frequency of mutations Percentage % Frequency in COSMIC1
p.K708N Unknown 1 2.3 ND
p.G709_T710.M Unknown 1 2.3 ND
p.G719 Sensitive 3 7.0 0.008
Exon 19 deletion Sensitive 16 37.2 0.157
p.S768I Resistant 1 2.3 ,0.5%
p.V769M Resistant 1 2.3 ,0.5%
p.D770GY Unknown 2 4.7 ,0.5%
p.D770_N771.SVD Resistant 1 2.3 ,0.5%
p.T790M Resistant 1 2.3 0.011
p.L833F Unknown 2 4.7 ,0.5%
p.A840T Unknown 2 4.7 ,0.5%
p.L858R sensitive 11 25.6 0.145
p.L861R sensitive 1 2.3 ,0.5%
Total 43 mutations* 100
1From the Cosmic data base (retrieved on 05-02-2013) containing 13030 mutations in 48781 samples.
*43 mutations were observed in 38 patients, 5 patients had double mutations.
The combination of double EGFR mutations were p.G719C, p.S768I, G719S L861R, G719C D770GY, L833F L858R and T790M L858R.
doi:10.1371/journal.pone.0070346.t002
Table 3. Distribution of codon 12/13 KRAS mutations in
advanced non-squamous cell lung carcinoma from this study








p.G12C 45 41.7 40.5
p.G12V 20 18.5 19.7
p.G12D 17 15.7 16.7
p.G12A 11 10.2 6.4
p.G13C 5 4.6 2.9
p.G12F 4 3.7 0.7
p.G12S 2 1.9 4.3
p.G13D 2 1.9 2.5
p.G12R 1 0.9 2
p.G13Y2 1 0.9 ND
Total 108 100% 100%
ND= Not Described.
1 From the Cosmic data base (retrieved on 05-02-2013) containing 3504
mutations in 21589 samples.
2 This mutation (c37_38GG.TT, p.G13Y) was detected in 2 independent non-
synchronous biopsies of the same patient.
Two KRAS mutations (p.V14L (not present at Cosmic) and p.L19F 2/2742
(present at Cosmic retrieved on 05-02-2013) were found outside codon 12/13
(considered as non-functional).
doi:10.1371/journal.pone.0070346.t003
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was performed (SCC/carcinoid). This means that from 74(75+3–
4) (17%) patients no results were obtained from mutational
analysis. In a total of 345 patients the tumor samples were
adequate for both EGFR and KRAS analysis. A single KRAS or
EGFR mutation analysis was performed in the tumor samples of
18 and 5 patients, respectively (Figure 1).
EGFR and KRAS mutations and metastases distribution
Using the clinical data from 303 patients, we were able to
analyze the preference for the known common metastatic regions
for the patients with NSCLC with KRAS and EGFR mutational
status. Pulmonary nodules (p=0.01), vertebral (p=0.03) and other
bone metastasis (p=0.04) were identified to be significantly
associated with EGFR mutations. No association was found
between EGFR mutations and pleural (p=0.15), cerebral (p=1.0),
hepatic (p=0.46) or adrenal (p=0.37) metastatic localizations.
None of these sites were associated with KRAS mutations.
Table 4. Distribution of EGFR and KRAS mutations and their wild types in histological NSCLC subtypes of 442 patients.
EGFR mutation % KRAS mutation % EGFR/KRAS WT % Insufficient material % Total
Adenocarcinoma 33 9.3 98 27.8 164 46.5 58 16.4 353
Squamous cell carcinoma 0 0 2 7.4 21 77.8 4 14.8 27
Adenosquamous 1 14.3 1 14.3 4 57.1 1 14.3 7
NSCLC NOS 3 5.4 9 16.4 32 58.2 11 20 55
Total 37* 8 110** 25 221 50 74 17 442
*Not including a patient with dual EGFR/KRAS mutation.
**Including 2 patient with a non-functional KRAS mutation and 1 patient with a dual EGFR/KRAS mutation.
doi:10.1371/journal.pone.0070346.t004
Figure 1. Flow chart for biopsy specimens sent in and result of mutation analysis. * 2 KRAS mutations are outside of the hotspot,
these are probably non functional.
doi:10.1371/journal.pone.0070346.g001
EGFR/KRAS Mutation Status in Dutch NSCLC Patients
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Survival analysis
In univariate analysis from the clinical data, large cell histology
(HR 1.8, 95% CI., 1.2–2.8, p,0.01) and spinal bone metastasis
(HR 1.5, 95% CI., 1.0–2.2, p=0.05) were associated with a worse
survival while EGFR mutation (HR 0.4, 95% CI., 0.2–0.7,
p,0.01) was associated with a better survival. In a multivariate
model, histology (large cell carcinoma, HR 2.2, 95% CI., 1.4–3.4,
p,0.01), spinal bone metastasis (HR 1.7, 95% CI., 1.2–2.6,
p,0.01), and mutational status (EGFR mutation, HR 0.3, 95%
CI., 0.1–0.6 p,0.01) were significantly associated with survival.
(Table 5).
When selecting patients who received EGFR TKI treatment in
the first or second line, the median overall survival after start of
this treatment was not reached in patients with EGFR mutation
(n = 14), 20 months (95% CI., 0–46, n = 14) for patients with
KRAS mutation, and 9 months (95% CI., 0–28, n = 31) for
patients with EGFR/KRAS WT. (Figure 2A and 2B).
Rare EGFR and KRAS mutations and response to
treatment.
Mutations that were not previously described in COSMIC DB
are described in table 6. Treatment with an EGFR TKI in patients
with these rare EGFR mutations did not result in clinical benefit
except in one patient who also had an additional activating EGFR
mutation.
Discussion
EGFR is a cell surface protein that leads to activation of
proliferation and invasion via different signal transduction
pathways [28]. KRAS is a downstream target of EGFR. Activating
or sensitizing mutations cause a constitutive activation of the
tyrosine kinase domain of the EGFR protein, by destabilizing the
autoinhibiting conformation [29]. EGFR TKI such as gefitinib
have increased binding abilities for these mutant proteins. The
ratios of this increased binding ability is up to 100 fold compared
to wild-type EGFR protein [29].
The two most common sensitizing EGFR mutations to EGFR
TKI, in frame deletions of exon 19 and the L858R mutation,
[19,30,31,32,33] represented over half of all EGFR mutation
patients. Other sensitizing aberrations were found in three patients
Figure 2. A: Overall survival in patients with non-small cell lung cancer treated with EGFR-TKI in the first and second line with or without an EGFR
mutation. The median overall survival for patients with EGFR mutations (n = 14) was not reached, in patients with EGFR/KRAS WT it was 9 months
(95% CI., 0–28 months, n = 31). 2B: Overall survival in patients with non-small cell lung cancer treated with EGFR-TKI in the first and second line with
or without KRAS mutation. The median overall survival for patients with KRAS mutations was 20 months (95% CI., 0–46, n = 14), in patients with EGFR/
KRAS WT it was 9 months (95% CI., 0–28 months, n = 31).
doi:10.1371/journal.pone.0070346.g002
Table 5. Univariate and multivariate hazards ratios for overall










Squamous 1.2 0.7–2.1 0.41 1.2 0.7–2.10.48
Large
Cell







0.4 0.2–0.7 ,0.01 0.3 0.1–0.6,0.01
KRAS
mutation
1.1 0.7–1.5 0.70 1.1 0.8–1.80.34
No test
performed




1.5 1.0–2.2 0.05 1.7 1.2–2.6,0.01
Brain 0.9 0.6–1.4 0.67
Lung 1.1 0.8–1.5 0.64
HR.1 means a shorter survival.
*denotes presence of metastasis at specific site.
doi:10.1371/journal.pone.0070346.t005
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having a G719X mutation and in another patient a L861R
mutation [33,34,35]. We observed 5 rare or previously unde-
scribed mutations (Table 2) and have characterized their response
to TKI treatment (Table 6). Of specific note is the p.D770GY
mutation, which was found in two patients, with different
response. The first of these patients had a combination of
p.D770GY and a p.G719C mutation while the second had only
a p.D770GY mutation. The first patient responded to EGFR TKI
and remains disease free after 15 months while the patient without
the secondary mutation had progressive disease diagnosed at
4 weeks. Previously 2 cases of this mutation were described
without information on tumor response [36,37]. Our data suggest
that the p.G770GY mutation does not provide benefit for EGFR
TKI treatment. Furthermore, we demonstrated that also patients
with one of the other 4 rare EGFR mutations (p.K708N,
p.G709_T710.M, p.L833F and p.A840T) had no benefit from
EGFR-TKI.
Small tumor samples mainly from bronchoscopic or transtho-
racic core biopsies may be a problem for adequate mutation
testing. We identified causes why mutational analysis at our lab
was not possible in 17% of patients. This was either due to
insufficient number of tumor cells (12%) or due to insufficient
DNA quality (4%) highlighting the need for adequate tumor tissue
selection for mutational analysis. Retrospective studies in which
long- term archived paraffin embedded tissue was used to
determine EGFR status showed a low proportion of adequate
tumor tissue available [1,2,3,4,5,6]. One way to obtain more
tumor cells is by repeated biopsies or cryobiopsies [38]. New
technological developments are far more sensitive than previously,
allowing fewer tumor cells both qualitatively (%) and quantita-
tively (absolute number) required for detecting mutations.
However, regarding tumor heterogeneity, this increased sensitivity
harbors an increased risk of sampling errors and detection of
minor clones that may be less relevant for therapy. A study showed
that about two thirds of all somatic mutations seemed not to be
detectable across every tumor region [39].
EGFR mutations occurred most often in TTF-1 positive
adenocarcinoma. Two recent studies showed this cell lineage
association [40,41]. Functionally, TTF-1 induced ROR-1 is
necessary to sustain the EGFR signaling pathway in lung
adenocarcinoma cell lines [42].
We identified the preference of EGFR mutant tumors to spread
to intrapulmonary and to both the vertebra and other bone
localizations. This contrasts with a study by Doebele et al, who
observed only a preference for hepatic metastatic spread in EGFR
mutant tumors [43].In contrast, we observed the typical miliary
Table 6. Rare EGFR and KRAS mutations and tumor response to EGFR TKI.
Mutations N Response Response Published response to
to chemotherapy to EGFR TKI EGFR TKI
EGFR mutations
p.K708N 1 PD PD (E) [47]PR with
gefitinib with
p.K708M
p.V769M 1 PR PD (E) [33,48];
No treatment
information
p. D770GY 1 PD PR (E) [36,37]
with a secondary No treatment
p.G719C mutation information
p.D770GY; 1 PR PD (G) [36,37]
without secondary No treatment
mutation information
p.L833F 1 PR PD (G) ND
(dual KRAS mutation)
p.A840T 2 PR/PR PD (E)/– ND
KRAS mutations
p.G13Y 1 PD – ND
p.V14L 1 PR – ND
PR is partial response, PD is progressive disease, – = no EGFR TKI treatment; (E) = erlotinib, (G) = gefitinib, ND=Not described.
doi:10.1371/journal.pone.0070346.t006
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pattern of tumors with EGFR exon 19 deletion as described
previously [44]. Our results for KRAS mutant tumors (71 patients)
were as described previously by Doebele et al (49 patients) [43].
In our population the outcome of patients with a KRAS
mutation responded similarly to KRAS WT both with respect to
chemotherapy and to EGFR TKI. Previously it was demonstrated
that patients with KRAS wild type have a better outcome than
patients with KRAS mutations when treated with an EGFR TKI
[22]. Other studies showed the presence of KRAS mutations in
lung cancer to be indicative of worse outcome regardless of the
treatment they received [45,46]. In the TITAN study, there was
some evidence for a higher risk of death in KRAS mutant tumor
patients treated with erlotinib compared to chemotherapy but
there was no elevated risk of tumor progression [4]. In our study,
we did not pool the EGFR mutation positive patients with the
EGFR/KRAS WT when comparing these patients with KRAS
mutant patients. As patients with EGFR mutations tend to have
better outcomes then EGFR WT patients, this could explain our
results.
In conclusion, we found in 10.9% and 30% of all the tested
patients an EGFR or KRAS mutation, respectively. We also
identified 5 novel or rare EGFR mutations and 2 novel KRAS
mutations in our population. Seventeen percent of patients had
inadequate tumor tissue to perform mutation analysis, mostly due
to insufficient tumor volume and/or percentage. There was no
difference in overall survival after starting EGFR-TKI in patients
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